Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Find a Researcher

Jun Qi, PhD

 No Ratings Available - Why Not?

Jun Qi, PhD

Researcher

Contact Information

  • Office Phone Number617-632-6629
  • Fax617-582-8580

Bio

Dr. Jun Qi is an Assistant Professor in Medicine at Cancer Biology Department in Dana-Farber Cancer Institute and Harvard Medical School.  Dr. Qi received his BS from Fudan University in China, and obtained his Ph.D. in Chemistry from University of Michigan in 2006, and completed his postdoctoral training at MIT in 2009.  Both his Ph.D. and postdoctoral studies have been focused on the total synthesis of natural compounds and the novel synthetic methodology development.  Dr. Qi joined Dana-Farber Cancer Institute in Dr. Bradner’s lab at in 2009, and focused his research on design and synthesis small molecule inhibitors targeting the gene regulation pathway for cancer therapy.  Dr. Qi has discovered a small molecule JQ1 that inhibits one of the bromodomain subfamily, BET bromodomain.  This discovery has been utilized to understand the role of epigenetic reader in variety of diseases, such as cancer, heart failure.  This small molecule was further optimized by Dr. Qi to clinical candidate, which started clinic trial recently.  Dr. Qi has also led the effort of developing new technologies, such as Chem-Seq.  Dr. Qi joined faculty members in Cancer Biology Department at DFCI in June, 2016, and will continue his effort to develop a platform consistent with chemistry, medicinal chemistry and chemical biology to understand the fundamental roles of epigenetic writer, reader and eraser in different diseases, specifically in cancers.

Research

    {line break}
  1. Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Brander JE, Sharpless NE. (2016) An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. (2016) Nature Medicine, in press.
    2. {line break}
  2. Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BE. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.  Nature Genetics, 2016, 48, 265-272. PMID: PMC26829750
    3. {line break}
  3. Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Hun SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D’Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Andres L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature, 2016, 529, 413-417. PMCID: PMC26735014
    4. {line break}
  4. Tanaka M, Roberts MJ, Qi J, Bradner JE. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Pharmaceutical Patent Analyst, 2015, 4, 261-284.
    5. {line break}
  5. Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu S, Qi J, Wang X, Delaney, C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature Medicine, 2015, 4, 335-343.
    6. {line break}
  6. Scholz C, Weinert BT, Wagner SA, Beli P, Miyake Y, Qi J, Jensen LJ, Streicher W, McCarthy AR, Westwood NJ, Lain S, Cox J, Matthias P, Mann M, Bradner JE, Choudhary C. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nature Biotechnology, 2015, 33, 415-423.
    7. {line break}
  7. Yi JS, Federation AJ, Qi J*, Dhe-Paganon S, Hadler M, Xu X, St Pierre R, Varca AC, Wu L, Marineau JJ, Smith WR, Souza A, Chory EJ, Armstrong SA, Bradner JE. Structure guided DOT1L probe optimization by label-free ligand displacement. ACS Chemical Biology, 2015, 10, 667-674.
    8. {line break}
  8. McKewon MR. Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE. Biased multicomponent reactions to develop novel bromodomain inhibitors. Journal of Medicinal Chemistry, 2014, 57, 9019-9027.
    9. {line break}
  9. Tang Y, Schubert S, Yu F, Oh S, Gholamin S, Mitra S, Cheshier SH, Willardson MI, Link BA, Lee A, Atwood SX, Whitson RJ, Tang JY, Oro AE, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, Balansay B, Woo P, Chen S, Ponnuswami A, Monje M, Qi J, Beroukhim R, Bradner JE, Wechsler-Reya R, Cho YJ. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine, 2014, 20, 732-740.
    10. {line break}
  10. Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC. RapidCap, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals Myc as a driver of Pten-mutant metastasis. Cancer Discovery, 2014, 4, 318-333.
    11. {line break}
  11. Chapuy B, McKewon MR, Lin CY, Monti S, Roemer MGM, Qi J, Raho PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell, 2013, 24, 777-790.
    12. {line break}
  12. Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, Loven J, Sigova AA, Smith WB, Lee TI, Bradner JE, Young RA. Genome-wide localization of small molecules. Nature Biotechnology, 2014, 32, 92-96.
    13. {line break}
  13. Anarnd P, Brown JD, Lin CY, Qi J, Zhang R, Artero-Calderon P, Ailati A, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM. BET bromodomains mediate transcriptional pause release in heart failure. Cell, 2013, 154, 569-582. F
    14. {line break}
  14. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greinger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discovery, 2013, 3, 308-323.
    15. {line break}
  15. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob, RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Matthieu S. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nature Communication, 2012, 3, 2304/1-2304/11.
    16. {line break}
  16. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE. Small-Molecule Inhibition of BRDT for Male Contraception. Cell, 2012, 150, 673-684.
    17. {line break}
  17. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi JW, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, Mckeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 2011, 146, 904-917.
    18. {line break}
  18. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies BRD4 as a therapeutic target in acute myeloid leukemia.  Nature, 2011, 478, 524-528.
    19. {line break}
  19. Filippakopoulos P, Qi J*, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, West N, Cameron MJ, Heightman TD, Thangue NL, Kung AL, French CA, Wiest O, Knapp S, Bradner JE. Selective inhibition of BET bromodomains.  Nature, 2010, 468, 1067-1073.
    20. {line break}
  20. Movassaghi M, Tjandra M, Qi J. Total synthesis of (-)-Himandrine. Journal of the American Chemical Society, 2009,  9648.
    21. {line break}
  21. Qi, J, Roush WR. Synthesis of precursors of the agalacto (exo) fragment of the quartromicins via an auxiliary-controlled exo-selective Diels-Alder reaction. Organic Letters, 2006, 2795.
    22. {line break}


Research Departments:

Research Website:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Longwood Center 2210
Boston, MA 02215
Get Directions

Top